TK2d

News

UCB bags FDA okay for first drug to treat rare disease TK2d

People living with thymidine kinase 2 deficiency (TK2d), a vanishingly rare and often fatal genetic disorder, finally have an approved therapy.

News

UCB drug for rare disease TK2d boosts survival

UCB's experimental medicine for TK2d, currently under regulatory review, offers hope to patients with the devastating rare disease.

News

FDA knocks back Pharming's bid for wider Joenja use

The FDA has turned down Pharming's bid to broaden the label of Joenja for rare immunodeficiency disorder APDS so it can be used in younger patients.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks